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ABSTRACT: Tuberculosis (TB) remains a major cause of mortality worldwide, and improved treatments are needed to combat
emergence of drug resistance. Inosine 5′-monophosphate dehydrogenase (IMPDH), a crucial enzyme required for de novo
synthesis of guanine nucleotides, is an attractive TB drug target. Herein, we describe the identiﬁcation of potent IMPDH
inhibitors using fragment-based screening and structure-based design techniques. Screening of a fragment library for
Mycobacterium thermoresistible (Mth) IMPDH ΔCBS inhibitors identiﬁed a low aﬃnity phenylimidazole derivative. X-ray
crystallography of the Mth IMPDH ΔCBS−IMP−inhibitor complex revealed that two molecules of the fragment were bound in
the NAD binding pocket of IMPDH. Linking the two molecules of the fragment aﬀorded compounds with more than 1000-fold
improvement in IMPDH aﬃnity over the initial fragment hit.
■ INTRODUCTION
Tuberculosis (TB) is a contagious infectious disease caused by
Mycobacterium tuberculosis (Mtb), which can be transmitted
through the air as droplets. The infection predominantly aﬀects
the lungs, but it can spread to other parts of the body, especially
in patients with a suppressed immune system.
The World Health Organization (WHO) has estimated that
nearly one-third of the world’s population is infected with Mtb,
leading to 1.8 million TB deaths in 2015.1 Although there has
been a slow decline in new TB cases and TB-related deaths in
recent years, the emergence and spread of multidrug resistant
(MDR) and extensively drug resistant (XDR) strains ofMtb has
increased the threat that this disease poses for global public
health. According to the WHO, approximately 480,000 cases of
MDR-TB emerged in 2015, and the cure rate of those patients
was only 50%.1
Current TB treatments require combinations of four ﬁrst-line
drugs, isoniazid, rifampicin, ethambutol, pyrazinamide, and
streptomycin, which must be taken for six months or longer.2
Resistant strains are not susceptible to the standard drugs, and
although MDR-TB is treatable using second-line drugs, such
treatments have a number severe side eﬀects.3 Consequently,
there is an urgent need for the development of novel and more
eﬀective drugs for the treatment of drug resistant TB.
Inosine-5′-monophosphate dehydrogenase (IMPDH, E.C.
1.1.1.205) has received considerable interest in recent years as
an important target enzyme for immunosuppressive,4 anti-
cancer,5,6 and antiviral drugs.7 Most recently, IMPDH has
emerged as a promising antimicrobial drug target.8−11
IMPDH catalyzes the ﬁrst unique step in the de novo synthesis
of guanine nucleotides, the oxidation of inosine 5′-mono-
phosphate (IMP) to xanthosine 5′-monophosphate (XMP) with
the concomitant reduction of the cofactor nicotinamide adenine
dinucleotide (NAD+) to NADH (Figure 1).12 XMP is then
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subsequently converted to guanosine 5′-monophosphate
(GMP) by a GMP synthetase.13
IMPDH has been deemed essential in every pathogen
analyzed to date, including Mtb, Staphylococcus aureus, and
Pseudomonas aeruginosa, which are three of the most serious
bacterial threats.14−16 However, this has been somewhat
contradictory,17 in comparing cell versus animal work. IMPDH
is an ubiquitous enzyme present in several eukaryotes, bacteria,
and protozoa.18 The IMPDH reaction involves two chemical
transformations. The ﬁrst step of the IMPDH catalyzed reaction
involves the attack of catalytic Cys on substrate IMP followed by
hydride transfer to NAD+, forming the covalent enzyme
intermediate E-XMP*. In the second step, E-XMP* is hydro-
lyzed to XMP.11 The enzyme exists in two diﬀerent
conformations, an open form that accommodates both the
substrate and cofactor during the ﬁrst step and a closed form
where the active site ﬂap moves into the NAD+-binding site for
the E-XMP* hydrolysis.19
In recent years, there has been considerable eﬀort aimed at
identifying small molecule inhibitors of IMPDH as potential
antitubercular agents. X-ray crystal structures of a truncated form
of the Mtb enzyme in complex with some of these compounds
have been reported.20−26
In antibacterial drug discovery, and especially in TB drug
discovery, high-throughput screening (HTS) typically identiﬁes
a number of leads that show high potency in vitro, but most did
not show any translation to an in vivo eﬀect. It is also inevitable
that the HTS libraries represent only a small fraction of possible
chemical space and so limit conﬁdence in ﬁnding a good starting
point for subsequent development. Phenotypic screens can
potentially lead to the identiﬁcation of a molecule that modiﬁes a
disease phenotype by acting on a previously undescribed target
or by acting simultaneously on more than one target.27 However,
for many of these hits the relevant target or targets has not yet
been identiﬁed, thus preventing further target-based optimiza-
tion of the compounds.28,29
The previously reported IMPDH inhibitors, such as
compounds 7759844 (1), MAD1, P41, VCC234718, and
DDD00079282 (Figure 2), were identiﬁed by phenotypic
screening or target based HTS of compound libraries.21,23−25
We have sought to develop IMPDH inhibitors using a
fragment-based approach. Fragment-based drug discovery
(FBDD) is now established in both industry and academia as
an alternative approach to high-throughput screening for the
generation of hits or chemical tools for drug targets.30
We have previously reported the discovery of several series of
novel and potent inhibitors using FBDD to target Mtb.
Previously we have reported the fragment elaboration strategies
that we have applied which have included fragment growing,
merging, and linking. Although fragment linking is conceptually
the most appealing strategy for fragment elaboration, in practice,
Figure 1. Purine nucleotide biosynthesis. The commonly occurring guanine nucleotide biosynthetic and salvage reactions are shown, as is the adenine
nucleotide biosynthetic pathway. The IMPDH reaction is boxed. NK, nucleoside kinase; HPRT, hypoxanthine phosphoribosyl transferase; XPRT,
xanthine phosphoribosyl transferase; GPRT, guanine phosphoribosyl transferase; GMPS, guanosine 5′-monophosphate synthetase; GMPR, guanosine
5′-monophosphate reductase; ADSS, adenylosuccinate synthetase; ADSL, adenylosuccinate lyase.
Figure 2. Structures of previously reported IMPDH inhibitors (α Ki values against IMP). All compounds showed uncompetitive inhibition with respect
to IMP.
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this strategy can be challenging where the choice of the optimal
fragment linker can be crucial.31,32
In the fragment-based approach, biophysical techniques are
usually used to identify small chemical compounds (fragments)
that bind with low aﬃnity to the drug target. X-ray
crystallography is then usually employed to establish the binding
mode of the fragment and to facilitate the design of elaborated
fragments. The availability of high-resolution X-ray crystal
structures of a truncated form of the IMPDH,21,24,25 in both
the substrate-free and substrate/ligand-bound forms, makes this
enzyme attractive for a fragment-based approach.
In this work, the discovery of a new class of potent nM
inhibitors of IMPDH using a FBDD approach is reported. A
library of 960 fragments was screened against Mth IMPDH
ΔCBS using a biochemical assay. The fragment hits from this
assay were examined using X-ray crystallography, and an X-ray
crystal structure of one of the fragment complexes was solved to a
resolution of 1.45 Å. Examination of the X-ray crystal structure
suggested a strategy of fragment-linking for optimization of this
fragment hit.
■ RESULTS AND DISCUSSION
Fragment Screening. An in-house fragment library
composed of 960 fragments was screened using a biochemical
assay against Mth IMPDH ΔCBS. Mth IMPDH, which shares
85% sequence identity withMtb IMPDH and is 100% identical in
the active site,24,25 was chosen for the fragment screening and
structural studies because it gave higher protein expression yields
and better diﬀracting crystals than the Mtb orthologue. IMPDH
activity was monitored spectrophotometrically by measuring the
formation of NADH at 340 nm. The biochemical assay was
performed at a fragment concentration of 1 mM, and hits were
retested in triplicate. Compound 1 (7759844) previously
Table 1. Structures and Activities for Compound 1 (7759844) and theMost Potent FragmentHits Found in the Screen againstMth
IMPDH ΔCBS
a% Inhibition at 10 μM.
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reported as IMPDH inhibitor was used as a positive control in
assays (Table 1).23
The screen resulted in 18 hits (1.9% hit rate), where a hit was
deﬁned as a compound that gave greater than 50% inhibition at a
concentration of 1 mM. A complete list of fragment hits
identiﬁed is included in Table 1. A number of common scaﬀolds
were observed, in particular phenylimidazole (fragments 2−4),
aminopyrazole (fragments 5−6), and naphthol (fragments 7−
11), and the remaining compounds contained a substituted
phenyl or a heterocyclic ﬁve membered ring (fragments 12−19).
The IC50 values of six of the most active fragments were
measured and the IC50 and ligand eﬃciency (LE) values of these
fragments are summarized in Table 2. The fragment screen
provided an array of hits with IC50 ranging from 325 μM to 674
μM and ligand eﬃciencies from 0.31 to 0.42. The inhibition
constant [Ki] with respect to both substrates IMP and NAD
+ was
determined by assaying various concentrations of each inhibitor
with ﬁve diﬀerent concentrations of substrate and a ﬁxed
saturating concentration of the cosubstrate. The inhibition data
for these fragments are summarized in Table 2. All compounds
yielded an uncompetitive inhibition pattern with respect to
NAD+ withKi values ranging from 262 to 525 μM. Fragments 14,
16, and 19 yielded a mixed inhibition with respect to IMP withKi
values ranging from 126 to 398 μM, and compounds 1, 2, 11, and
18 yielded an uncompetitive inhibition with Ki values ranging
from 361 to 609 μM.
Inhibition constants of compound 2 toward full-length Mtb
IMPDH were also determined. Compound 2 inhibited full-
lengthMtb IMPDH enzyme with a Ki value of 572± 14 μMwith
IMP as the substrate and a Ki value of 534± 18 μMwith NAD as
the substrate, which are similar to the Ki values observed for the
Mth IMPDH ΔCBS enzyme.
X-ray Structure of Compounds 1 (7759844) and 2.
Compound 1 and the six fragment hits (2, 11, 14, 16, 18, and 19)
were selected for structural characterization using X-ray
crystallography by soaking into preformed crystals of Mth
IMPDH ΔCBS as previously described.20 After molecular
replacement, clear electron density was observed in the 2F0 −
Fc diﬀerence map (σ = 3.0) for IMP, and in addition density was
observed for one molecule of compound 1 (Figure 3A) and two
molecules of compound 2 (Figure 3B), which were partially
occupying the NAD+ binding site. None of the other fragments
Table 2. IC50, Ligand Eﬃciency, and Alpha Ki Values of
Fragment Hits and Compound 1 (7759844) against Mth
IMPDH ΔCBS
Compd IC50 (μM) (LE)
a IMP αKi (μM) NAD αKi (μM)
1 0.77 ± 0.06 (0.40) 0.86 ± 0.03 (UC)b 0.55 ± 0.02 (UC)
2 674 ± 53 (0.36) 609 ± 3 (UC) 512 ± 23 (UC)
11 336 ± 6 (0.39) 361 ± 53 (UC) 310 ± 30 (UC)
14 400 ± 7 (0.42) 238 ± 6 (Mixed) 262 ± 39 (UC)
16 433 ± 60 (0.31) 398 ± 81 (Mixed) 525 ± 64 (UC)
18 512 ± 37 (0.37) 554 ± 70 (UC) 452 ± 26 (UC)
19 325 ± 9 (0.37) 126 ± 34 (Mixed) 355 ± 47 (UC)
aLigand eﬃciency was calculated using the equation LE = (1.37 ×
pIC50)/HA, where HA means heavy atom, i.e., a non-hydrogen atom.
bUC: Uncompetitive inhibition.
Figure 3. X-ray crystal structure of compounds 1 and 2 bound to Mth IMPDH ΔCBS. Ligand interactions are represented as dotted lines; hydrogen
bonds are represented in red, polar interactions in orange, ionic interactions in yellow, and aromatic and π interactions in green dotted lines. Protein−
ligand interactions were analyzed using Arpeggio. (a) Interactions made by 1 (green) in the X-ray crystal structure of the complex of IMPDH with IMP
(orange). (b) Interactions made by 2 (yellow) in the X-ray crystal structure of the complex of IMPDHwith IMP. (c) Structural alignment of the IMPDH
crystal structures of 1 (green) and 2 (yellow).
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(11, 14, 16, 18, and 19) showed any electron density in the X-ray
crystal structures. Although the kinetic studies of compounds 1
and 2 suggested that these two compounds are uncompetitive
with respect to NAD+, the binding mode of compounds 1 and 2
closely resembles that of other previously reported uncompeti-
tive inhibitors of Mtb IMPDH.21,24,25 It has been proposed that
the uncompetitive mode of inhibition of IMPDH inhibitors with
respect to NAD+ is consistent with their binding preferentially to
the covalent IMPDH-XMP* intermediate after NADH has been
released.24,25,33
The structure of Mth IMPDH ΔCBS with compound 1
showed that the inhibitor binds in the NAD pocket in a near
identical manner to our recently described IMPDH inhib-
itors.24,25 Compound 1 formed strong π interactions with the
hypoxanthine group of IMP, P45′, Y471′, and polar interactions
with G409, E442, P45′, and G470′. The electron density revealed
twomolecules of compound 2within the NAD binding pocket of
IMPDH. One molecule of compound 2 stacked with IMP,
forming extensive π interactions with the hypoxanthine group of
IMP. This fragment was further stabilized through polar
interactions, hydrogen bonds, and π interactions to surrounding
residues in the active site pocket, including A269, G318, and
E442. The other molecule of compound 2 sits closer to the
opening of the active site, making polar interactions with N273
and E442, and π interactions with H270 and Y471′.
A comparison of the structure of Mth IMPDH ΔCBS with
compound 1 with the fragment 2 structure shows that the two
molecules of 2 mimic the position of the larger inhibitor 1
(Figure 3C).
Fragment Elaboration. Fragment 2 was selected as the
starting point for exploration because of the ease of synthetic
modiﬁcation and the availability of a X-ray crystal structure to
guide the optimization. For chemical elaboration of 2, fragment
linking as well as fragment growing were considered. As the two
molecules of fragment 2 are found to bind in adjacent regions of
the target protein, the fragment-linking approach was the more
attractive option. However, before fragment linking, fragment 2
was further optimized with the aim of improving the binding
aﬃnity. The structures and inhibitory activities of these
compounds against Mth IMPDH ΔCBS are summarized in
Tables 3 and 4. The corresponding data for fragment 2 have also
been included for comparative purposes.
All compounds were evaluated at a concentration of 100 μM
with Mth IMPDH ΔCBS.
Fragment Growing. The fragment-growing strategy in-
volves using structure-based drug design to form additional
interactions by growing out from the starting fragment.
Fragment 2 was modiﬁed at the 2-position of the imidazole
ring to explore the introduction of various aromatic rings linked
by a thioacetamide (20−22) to form π interactions with the
hypoxanthine group of IMP (Figure S1). Such modiﬁcations
gave compounds with improved Mth IMPDH ΔCBS inhibition.
The phenyl and benzofuran derivatives (20 and 21) showed 13
and 31% inhibition, respectively. Mth IMPDH ΔCBS inhibition
was shown to be sensitive to minor modiﬁcations of the phenyl
substituent groups; for example, the 4-iodo substituted 22
showed 30% inhibition at 100 μM, whereas the nonsubstituted
compound, 20, showed 13% inhibition at the same concen-
tration. The eﬀect of the removal of the 4-bromo group was
investigated and compounds 23−25 were synthesized. Removal
of the bromo substituent in compounds 20−22 (13−31%
inhibition at 100 μM) was tolerated (23−25, 3−46% inhibition
at 100 μM). The importance of the aromatic amide linked by a
thioacetamide was subsequently examined. Replacing the phenyl
with isopropyl (26) resulted in complete loss of activity.
Substitution of the thioacetamide by a thioacetic acid also led
to a complete loss in activity (compounds 27 and 28).
Fragment Linking and SAR. Examination of the X-ray
crystal structure of the previously reported inhibitor 1 when
overlaid with fragment 2 revealed that the distance between the
4-position of the phenyl ring of fragment 2 and the 2-position of
the imidazole ring represents the closest approach of the
molecules (Figure S1). On the basis of this structural
Table 3. Structures and Activities for Fragment 2 and
Compounds 20−28 against Mth IMPDH ΔCBS
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information, three diﬀerent linkers were designed to connect the
two copies of the fragment 2 at these positions (compounds 29−
31). Initially, a thioacetamide and urea linker moieties were
examined. Compounds 29 and 30 showed 20% and 56% ofMth
IMPDH ΔCBS inhibition, respectively, at 100 μM (Table 4).
Interestingly, compound 30 showed a 12-fold improvement in
Mth IMPDH ΔCBS inhibitory activity with an IC50 of 58 μM,
compared to the fragment 2.
The lactate linker was then used, but all attempts to link 4-
phenylimidazole with 4-(4-bromophenyl)-1H-imidazole were
unsuccessful. We therefore decided to synthesize compound 31,
which contains 1-methyl-4-phenyl-1H-imidazole and 4-(4-
Table 4. Structures and Activities for Fragment 2 and Compounds 29−35 against Mth IMPDH ΔCBS
aLigand eﬃciency was calculated using the equation LE = (1.37 × pIC50)/HA, where HA means heavy atom, i.e., a non-hydrogen atom.
bND: not
determined. IC50 values were determined for compounds that showed >50% inhibition.
c%Inhibition at 10 μM.
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bromophenyl)-1H-imidazole linked with a lactate analogue, as in
compound 1. Compound 31 (Table 4) showed markedly
improved Mth IMPDH ΔCBS inhibition with a LE of 0.29 and
IC50 of 0.52 μM,which is 1300-foldmore potent compared to the
fragment 2. Although compound 31 binds in the cofactor site, the
mechanism of inhibition can vary depending on its relative
aﬃnities for the E·IMP and E-XMP* complexes.8,11 Kinetic
evaluation of compound 31 showed the mode of Mth IMPDH
ΔCBS inhibition was uncompetitive with respect to both IMP
and the NAD+ cofactor (see Figure S2, Supporting Information)
with a Ki value of 0.30± 0.02 μMwith IMP as the substrate and a
Ki value of 0.20 ± 0.01 with NAD as the substrate.
Inhibition constants of compound 31 toward full-length Mtb
IMPDH were also determined. Compound 31 inhibited full-
length Mtb IMPDH enzyme with a Ki value of 0.61 ± 0.05 μM
with IMP as the substrate and a Ki value of 0.39 ± 0.02 μM with
NAD as the substrate. The inhibition constants were consistent
with the data using the Mth IMPDH ΔCBS enzyme.
Removal of the bromo substituent in compound 29 to give
compound 32 was well tolerated (Table 4). The importance of
the imidazole group for the inhibitory activity against Mth
IMPDH ΔCBS was conﬁrmed by replacing of the 4-(4-
bromophenyl)-1H-imidazole substituent of compound 31 with
4-(4-bromophenyl)oxazole (33) which resulted in a 4-fold loss
of activity (Table 4). Replacing the 4-(4-bromophenyl)-1H-
imidazole of 31 by a phenyl (34) resulted in complete loss of
activity (Table 4). However, the 4-iodophenyl derivative 35
demonstrated slightly improved activity (IC50 = 0.47 μM, LE =
0.34) compared to compounds 31 (IC50 = 0.52 μM, LE = 0.29)
and 1 (IC50 = 0.77 μM, LE = 0.40). It is noteworthy that LE of
compound 35was comparable to that of the original fragment hit
2 (LE = 0.36) and other reported IMPDH inhibitors.34
The importance of the 4-bromo substituent on the phenyl ring
in compound 31 was also explored (compounds 36−39, Table
5). Removal of the bromo substituent (36) resulted in a 5-fold
loss in activity, whereas replacing this group with an iodine (39)
or a morpholine ring (37) resulted in less than 1.3-fold loss in
activity. The electronic nature of the substituent in this position
had little eﬀect on inhibitory activity. For example, an electron-
donating methoxy (38) retained activity comparable to that of
the bromine derivative (31). Among them, imidazoles 31, 37−
38, and 39 were found to be potent inhibitors of Mth IMPDH
ΔCBS with IC50 values ranging from 520 to 690 nM.
The (S)-isomer of 31 was found to bind preferentially (Table
5), with the racemate 31 having approximately half the Mth
IMPDHΔCBS inhibition of the (S)-isomer 31. This observation
accords with the results previously reported for other series of
IMPDH inhibitors.21,35
X-ray Structure of Compound 31. From crystals soaked
with compound 31, the 2F0 − Fc diﬀerence map (σ = 3.0)
revealed strong density for the inhibitor. The structure of
compound 31 (Figure 4A) showed that it bound in a nearly
identical manner to compounds 1 and 2 in the NAD binding
pocking (Figure 4B), stacking with IMP, and maintaining the
interactions with H270, N273, E442, and P45 and Y471 from the
neighboring subunit. Compound 31 made additional inter-
actions in the binding pocket, including polar interactions with
D267 and N297.
Whole-Cell Activity againstMtb.The whole-cell activity of
the most potent analogues 31, 33−39, and (S)-31 in vitro was
determined against Mtb H37Rv (see Table S1, Supporting
Information). No signiﬁcant inhibition of bacterial growth was
detected for any of the compounds (MIC90 ≥ 50 μM) over the
tested concentration range (0−100 μM). There are currently
ongoing eﬀorts to explain the lack of eﬃcacy of the potent Mth
IMPDH ΔCBS inhibitors described which could be caused by
low membrane permeability, poor metabolic stability, and/or
drug-eﬄux mechanisms.
Synthetic Chemistry. Compounds 20−29 and 32 were
synthesized from 4-phenyl-1H-imidazole-2-thiol or 4-(4-bromo-
phenyl)-1H-imidazole-2-thiol according to the sequence de-
scribed in Scheme 1. Thioacetic derivatives 27 and 28 were
prepared by treatment of 4-phenyl-1H-imidazole-2-thiol or 4-(4-
bromophenyl)-1H-imidazole-2-thiol with 2-chloroacetic acid in
the presence of NaOH followed by neutralization with
hydrochloric acid.
Thioacetamide 26was synthesized by amide coupling between
thioacetic derivative 28 and isopropylamine. Similarly, thio-
acetamides 20−25, 29, and 32 were prepared by cross-linking 4-
phenyl-1H-imidazole-2-thiol or 4-(4-bromophenyl)-1H-imida-
zole-2-thiol with α-chloroacetamides 40−43, which were
obtained by acylation of anilines with various substituents with
chloroacetyl chloride.
The synthesis of urea 30 was achieved as shown in Scheme 2
by coupling amine 44 and N-(4-(1H-imidazol-4-yl)phenyl)-1H-
imidazole-1-carboxamide, which was obtained from commer-
cially available 4-(1H-imidazol-4-yl)aniline as a crude interme-
diated, in the presence of N,N-diisopropylethylamine. Amine 44
was synthesized from benzyl ((5-(4-bromophenyl)-1H-imida-
Table 5. Structures and Activities for Compounds 31, 36−39,
and (S)-31 against Mth IMPDH ΔCBS
aLigand eﬃciency was calculated using the equation LE = (1.37 ×
pIC50)/HA, where HA means heavy atom, i.e., a non-hydrogen atom.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01622
J. Med. Chem. 2018, 61, 2806−2822
2812
zol-2-yl)methyl)carbamate,36 followed by the deprotection of
the benzyloxycarbonyl group under acidic condition.
Imidazole derivatives 31, 36−38, and 39 were prepared
following the synthetic procedure outlined in Scheme 3. 2-
Aminoimidazoles 50−54 were synthesized according to a
published microwave-assisted protocol.37 In brief, 2-amino-
imidazoles 50−54were prepared by reaction of the commercially
available α-haloketones and N-acetylguanidine, followed by
deacetylation (Scheme 3). Acid 59 was synthesized starting with
imidazole 55, which was prepared by reaction of 2-bromo-4′-
hydroxyacetophenone with formamide as reported previously.38
The phenol 57 was synthesized by alkylation of imidazole 55,
followed by deprotection of the methyl ether with BBr3.
Substituted phenol 57 was converted to the ether 58 upon
treatment with methyl 2-bromopropionate in the presence of
Cs2CO3. Enantiomerically pure phenyl ethers were synthesized
by using Mitsunobu reaction conditions with ethyl D-lactate
(Scheme 4). After the hydrolysis of the ester group, the resulting
carboxylic acid 59 was treated with thionyl chloride to give the
acid chloride 60, which was reacted with 2-aminoimidazoles 50−
54 to aﬀord imidazole derivatives 31, 36−38, and 39.
The syntheses of 2-acylaminooxazole 33 and amides 34−35
were achieved as shown in Scheme 5. 2-Acylaminooxazole
derivative 33 was obtained by coupling the acid chloride
derivative 60 with 2-aminooxazole derivative 61, which was
prepared by reaction of 2,4′-dibromoacetophenone with urea.
Similarly, amides 34−35 were prepared by coupling the
corresponding anilines with the acid chloride derivative 60.
■ CONCLUSIONS
FBDD has emerged as a robust approach to identify small
molecules that bind to a wide range of therapeutic targets.
Fragment elaboration strategies have resulted in the develop-
ment of a number of compounds that have progressed into
clinical trials. Within the area of TB drug discovery, a number of
HTS and phenotypic screens have been performed during the
past decade. Although HTS identiﬁed a number of leads that
show high potency in vitro, the translation to an in vivo eﬀect has
proven challenging.
Figure 4.X-ray crystal structure of compound 31 bound toMth IMPDH
ΔCBS. Protein−ligand interactions were analyzed using Arpeggio. (a)
Interactions made by 31 in the X-ray crystal structure of the complex of
IMPDH with IMP (orange). Ligand interactions are represented as
dotted lines; hydrogen bonds are represented in red, polar interactions
in orange, ionic interactions in yellow, and aromatic and π interactions in
green dotted lines. (b) Structural alignment of the IMPDH crystal
structures of 1 (lilac), 2 (yellow), and 31 (green).
Scheme 1. Synthesis of Thioacetamide and Thioacetic Derivatives 20−29 and 32a
aReagent and conditions: (a) 2-chloroacetic acid, NaOH, EtOH, 80 °C, 69−72%; (b) isopropylamine, HATU, DIPEA, EtOAc, rt, 73%; (c)
chloroacetyl chloride, TEA, DCM, rt, 89−99%; (d) NaOH, MeOH, H2O, 70 °C, 69−96%.
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This study illustrates the successful application of a fragment-
based approach followed by fragment optimization to obtain
nanomolar aﬃnity ligands of IMPDH. A library of 960 fragments
were screened against Mth IMPDH ΔCBS, and from the screen
the phenylimidazole fragment hit 2 (IC50 = 674 μM) was
identiﬁed. Kinetic experiments showed that 2 was an
uncompetitive inhibitor of Mth IMPDH ΔCBS with respect to
NAD+ and IMP. Twomolecules of the fragment 2were shown to
bind at the NAD binding site of the enzyme. The X-ray crystal
structure also revealed that one molecule of fragment 2 makes π
interactions with IMP and the other molecule sits closer to the
opening of the active site, making polar interactions with N273
and E442 and π interactions with H270 and Y471′. This provides
potential for further optimization of fragment 2. To explore
better the possibilities given by fragment 2, fragment-linking and
fragment-growing strategies were employed, resulting in low
micromolar to nanomolar aﬃnity compounds. Among them,
compounds 31, 35, and 37− 39 were the most potent IMDPH
inhibitors of the series described in this work with IC50 values
between 0.47 and 0.69 μM, which represent >1000-fold
improvement in Mth IMPDH ΔCBS potency over the initial
fragment hit. Compound 31 was shown to bind at the NAD
binding site of the enzyme, and the X-ray crystal structure also
revealed that it makes π interactions with IMP, maintaining the
interactions with H270, N273, E442, and P45 and Y471 from the
neighboring subunit. Moreover, compound 31 made additional
interactions in the binding pocket, including polar interactions
with D267 and N297. A comparison of this structure with the
fragment 2 structure shows that the twomolecules of 2mimic the
position of the larger inhibitor 31. This is the ﬁrst example of
Scheme 2. Synthesis of Urea 30a
aReagent and conditions: (a) CDI, THF, rt, quant.; (b) HCl (4 M), dioxane, 100 °C, quant.; (c) DIPEA, DMF, rt, 26%.
Scheme 3. Synthesis of 2-Acylaminoimidazole Derivatives 31, 36−38, and 39a
aReagent and conditions: (a) acetylguanidine, CH3CN, μW, 100 °C, 71−88%; (b) (1) 20% H2SO4, MeOH:H2O (1:1 v/v), μW, 100 °C; (2) aq
Na2CO3, 79−95%; (c) formamide, 150 °C, 99%; (d) CH3I, Cs2CO3, DMF, rt, 88%; (e) BBr3 (1 M in DCM), −78 °C to rt, DCM, 96%; (f) Cs2CO3,
methyl 2-bromopropionate, DMF, 60 °C, 92%; (g) NaOH, THF:H2O (2:1 v/v), 80 °C, 65%; (h) SOCl2, 80 °C, quant.; (i) TEA, DCM, 40 °C, 61−
72%.
Scheme 4. Synthesis of the S-Enantiomer of 31a
aReagent and conditions: (a) (1) Ethyl D-lactate, PPh3, DEAD, THF, rt; (2) NaOH, THF:H2O (2:1 v/v), rt, 56%; (b) SOCl2, 80 °C, quant.; (c) 50,
TEA, DCM, 40 °C, 69%.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01622
J. Med. Chem. 2018, 61, 2806−2822
2814
utilizing the fragment-based approach speciﬁcally to identify new
potent inhibitors of IMPDH. Further structural optimization to
improve the cellular activity of these analogues is ongoing with
the aim of developing novel classes of anti-TB agents.
■ EXPERIMENTAL SECTION
1. Chemistry. 1.1. General Experimental Methods. Solvents were
distilled prior to use and dried by standard methods. Unless otherwise
stated, 1H and 13C NMR spectra were obtained in CDCl3, MeOD, or
DMSO-d6 solutions using either a Bruker 400 MHz AVANCE III HD
Smart Probe, 400 MHz QNP cryoprobe, or 500 MHz DCH cryoprobe
spectrometer. Chemical shifts (δ) are given in ppm relative to the
residual solvent peak (CDCl3:
1H, δ = 7.26 ppm; 13C, δ = 77.16 ppm),
and the coupling constants (J) are reported in hertz (Hz). Optical
rotations were measured on a PerkinElmer Polarimeter 343 at 589 nm
(Na D-line), and speciﬁc rotations are reported in 10−1 deg cm2 g−1.
Microwave reactions were performed using a Biotage Initiator system
under reaction conditions as indicated for each individual reaction.
Reactions were monitored by TLC and LCMS to determine
consumption of starting materials. Flash column chromatography was
performed using an Isolera Spektra One/Four puriﬁcation system and
the appropriately sized Biotage SNAP column containing KP-silica gel
(50 μm). Solvents are reported as volume/volume eluent mixture where
applicable.
High resolution mass spectra (HRMS) were recorded using a Waters
LCT Premier Time of Flight (TOF) mass spectrometer or a Micromass
Quadrapole-Time of Flight (Q-TOF) spectrometer.
Liquid chromatography mass spectrometry (LCMS) was carried out
using an Ultra Performance Liquid Chromatographic system (UPLC)
Waters Acquity H-class coupled to a Waters SQ Mass Spectrometer
detector. Samples were detected using a Waters Acquity TUV detector
at 2 wavelengths (254 and 280 nm). Samples were run using an Acquity
UPLCHSS column and a ﬂow rate of 0.8 mL/min. The eluent consisted
of 0.1% formic acid in water (A) and acetonitrile (B); gradient, from
95% A to 5% A over a period of 4 or 7 min.
All ﬁnal compounds had a purity greater than 95% by LCMS analysis.
General Method A: Synthesis of Thioacetamides 20−25, 29, and
32. To a solution of the 2-chloroacetamide derivative (0.17 mmol) in
MeOH (8 mL) was added 4-(4-bromophenyl)-1H-imidazole-2-thiol or
4-phenyl-1H-imidazole-2-thiol (0.17 mmol), followed by a solution of
NaOH (0.67 mmol) in H2O (2.5 mL). The reaction mixture was stirred
at 70 °C for 3 h. After cooling to rt, the solvents were removed in vacuo
and the resulting residue was taken up in 30 mL of EtOAc and washed
with H2O (15 mL). The aqueous layer was extracted with EtOAc (3 ×
30 mL) and the combined organic layers were washed with brine and
dried over MgSO4. Filtration and evaporation aﬀorded crude products,
which were puriﬁed as indicated below.
General Method B: Synthesis of Thioacetic Derivatives 27 and 28.
A solution of 4-phenyl-1H-imidazole-2-thiol or 4-(4-bromophenyl)-1H-
imidazole-2-thiol (2.80 mmol) and NaOH (5.0 mmol) in EtOH (5 mL)
was reﬂux for 1 h. After cooling to rt, a solution of 2-chloroacetic acid
(2.80 mmol) in EtOH (2 mL) was added. The reaction was stirred at
reﬂux for an additional 3 h and then cooled to 0 °C. The reactionmixture
was diluted with cold water (5 mL) and acidiﬁed with 1 M HCl. The
precipitated product was collected by ﬁltration and washed with DCM
(2 × 2 mL).
General Method C: Synthesis of Compounds 31, 33, and 36−39. A
mixture of acid 59 (0.20 mmol) and SOCl2 (2 mL) was heated at 80 °C
for 2 h. The solvent was removed under reduced pressure to give the acid
chloride 60 as a white solid. The resulting solid was immediately
dissolved in anhydrous DCM, and the resulting solution was added
slowly dropwise at 0 °C to a solution of the corresponding substituted 2-
aminoimidazoles (0.20 mmol) and TEA (0.80 mmol) in anhydrous
DCM (5 mL). The reaction mixture was stirred at 40 °C for 36 h and
then diluted with DCM (20 mL) and washed with saturated aqueous
NaHCO3. The aqueous phase layer was then extracted with DCM (2 ×
20 mL), and the combined organic layers were dried over MgSO4 and
ﬁltered, and the solvent was removed under reduced pressure to aﬀord a
yellow oil, which was puriﬁed by ﬂash chromatography, eluting with the
solvent system speciﬁed.
General Method D: Synthesis of Amides 34−35. A mixture of acid
59 (0.20 mmol) and SOCl2 (2 mL) was heated at 80 °C for 2 h. The
solvent was removed under reduced pressure to give 60 as a white solid.
The resulting solid was immediately dissolved in anhydrous DCM, and
the resulting solution was added slowly dropwise at 0 °C to a solution of
the corresponding aniline (0.20 mmol) and triethylamine (0.80 mmol)
in anhydrous DCM (5mL). The reactionmixture was stirred at rt for 4 h
and then diluted with DCM (20 mL) and washed with saturated
aqueous NaHCO3. The aqueous phase layer was then extracted with
DCM (2 × 20 mL), and the combined organic layers were dried over
MgSO4 and ﬁltered, and the solvent was removed under reduced
pressure to aﬀord a yellow oil, which was puriﬁed by ﬂash
chromatography, eluting with the solvent system speciﬁed.
General Method E: Synthesis of α-Chloroacetamides 40−43. Et3N
(4.77 mmol) followed by a solution of chloroacetyl chloride (4.77
mmol) in DCM (3 mL) were added to a stirred solution of the
corresponding aniline (4.38 mmol) in DCM (5 mL) at rt. The reaction
mixture was stirred at rt for 2−4 h. The reaction was then diluted with
DCM (20 mL) and washed with saturated aqueous NaHCO3, 1 MHCl,
and brine and dried over anhydrous MgSO4, and the solvent was
removed under reduced pressure. Compound 43 was puriﬁed by ﬂash
chromatography eluting with the solvent system speciﬁed, although
other analogues were used in subsequent reactions without further
puriﬁcation.
Scheme 5. Synthesis of 2-Acylaminooxazole Derivative 33 and Amides 34−35a
aReagent and conditions: (a) urea, CH3CN, 80 °C, 78%; (b) TEA, DCM, rt (for 34 and 35) or 40 °C (for 33), 64−76%.
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General Method F: Synthesis of Substituted N-(1H-Imidazol-2-
yl)acetamides 45−49. A mixture of the corresponding 2-bromoaceto-
phenone derivative (0.38 mmol) and acetylguanidine (1.13 mmol) in
anhydrous acetonitrile (3 mL) was heated at 100 °C using microwave
irradiation for 15 min. The solvent was removed, and the residue was
taken in H2O (3mL) and ﬁltered, and the solid was washed with H2O (2
mL× 2) and DCM (2mL). The solid obtained was used in the next step
without further puriﬁcation.
General Method G: Synthesis of Substituted 2-Aminoimidazoles
50−54.To a solution of the corresponding substitutedN-(1H-imidazol-
2-yl)acetamides (0.31 mmol) in a 1:1 v/v mixture of MeOH and H2O
(2.4 mL) was added concentrated H2SO4 (0.6 mL), and the reaction
mixture was heated at 100 °C under microwave irradiation for 15−30
min. The reaction mixture was concentrated, and the resulting residue
was resuspended in H2O (5 mL), and a saturated aqueous Na2CO3 was
added until pH 8. The product was extracted into EtOAc (3 × 40 mL).
The combined organic fractions were dried overMgSO4, and the solvent
was removed under reduced pressure. The resulting solid was used in the
next reaction without further puriﬁcation.
2-((4-(4-Bromophenyl)-1H-imidazol-2-yl)thio)-N-phenylaceta-
mide (20). Compound 40 (29 mg, 0.17 mmol) was reacted with 4-(4-
bromophenyl)-1H-imidazole-2-thiol (43 mg, 0.17 mmol) according to
general method A. Puriﬁcation by ﬂash chromatography (1−20% v/v
MeOH in DCM) aﬀorded 20 (59 mg, 0.15 mmol, 89% yield) as a white
solid. 1H NMR (400 MHz, MeOD) δ 7.62 (br s, 2H), 7.56−7.39 (m,
5H), 7.36−7.17 (m, 2H), 7.13−7.00 (m, 1H), 3.82 (s, 2H) ppm. 13C
NMR (100 MHz, MeOD) δ 169.6, 141.3, 139.6, 132.8, 129.8, 129.8,
127.5, 125.5, 121.4, 121.2, 121.2, 116.7, 39.6 ppm. LCMS (ESI−) m/z
388.0 [M − H]−, retention time 2.20 min (100%). HRMS (ESI+): m/z
calculated for C17H15BrN3OS [M + H]
+: 388.0119. Found: 388.0121.
N-(Benzofuran-5-yl)-2-((4-(4-bromophenyl)-1H-imidazol-2-yl)-
thio)acetamide (21). Compound 41 (36 mg, 0.17 mmol) was reacted
with 4-(4-bromophenyl)-1H-imidazole-2-thiol (43 mg, 0.17 mmol)
according to general method A. Puriﬁcation by ﬂash chromatography
(1−20% v/v MeOH in DCM) aﬀorded 21 (70 mg, 0.16 mmol, 96%
yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 12.50 (br s,
1H), 10.35 (br s, 1H), 7.94 (dd, J = 10.6, 2.0 Hz, 2H), 7.73−7.64 (m,
2H), 7.52−7.44 (m, 4H), 7.34 (dd, J = 8.8, 2.2 Hz, 1H), 6.91 (dd, J = 2.2,
1.0 Hz, 1H), 3.99 (s, 2H) ppm. 13C NMR (100 MHz, DMSO-d6) δ
166.5, 150.8, 146.7, 140.2, 139.9, 134.3, 133.6, 131.4, 127.4, 126.2, 119.0,
116.9, 115.7, 111.6, 111.3, 107.0, 37.9. LCMS (ESI−) m/z 428.0 [M −
H]−, retention time 2.22 min (100%). HRMS (ESI+): m/z calculated
for C19H15BrN3O2S [M + H]
+: 428.0068. Found: 428.0065.
2-((4-(4-Bromophenyl)-1H-imidazol-2-yl)thio)-N-(4-iodophenyl)-
acetamide (22).Compound 42 (50mg, 0.17mmol) was reacted with 4-
(4-bromophenyl)-1H-imidazole-2-thiol (43 mg, 0.17 mmol) according
to general method A. Puriﬁcation by ﬂash chromatography (1−20% v/v
MeOH in DCM) aﬀorded 22 (60 mg, 0.11 mmol, 69% yield) as a white
solid. 1H NMR (500 MHz, MeOD) δ 7.63−7.58 (m, 4H), 7.56−7.45
(m, 3H), 7.38−7.31 (m, 2H), 3.81 (s, 2H) ppm.13C NMR (125 MHz,
MeOD) δ 169.6, 139.6, 138.9, 132.7, 127.5, 127.1, 123.0, 116.6, 111.4,
88.1, 39.7 ppm. LCMS (ESI−) m/z 511.7 [M − H]−, retention time
2.30 min (100%). HRMS (ESI+): m/z calculated for C17H14BrIN3OS
[M + H]+: 513.9086. Found: 513.9087.
N-Phenyl-2-((4-phenyl-1H-imidazol-2-yl)thio)acetamide (23).
Compound 40 (42 mg, 0.25 mmol) was reacted with 4-phenyl-1H-
imidazole-2-thiol (44 mg, 0.25 mmol) according to general method A.
Puriﬁcation by ﬂash chromatography (1−20% v/v MeOH in DCM)
aﬀorded 23 (61 mg, 0.20 mmol, 82% yield) as a white solid. 1H NMR
(500 MHz, MeOD) δ 7.71 (br s, 2H), 7.54−7.49 (m, 2H), 7.47 (br s,
1H), 7.35 (t, J = 7.4 Hz, 2H), 7.31−7.20 (m, 3H), 7.11−7.03 (m, 1H),
3.83 (s, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 168.3, 142.7, 139.5,
138.5, 138.2, 128.4, 128.3, 126.7, 124.4, 124.1, 123.7, 119.8, 38.3 ppm.
LCMS (ESI−) m/z 308.0 [M − H]−, retention time 1.82 min (95%).
HRMS (ESI+): m/z calculated for C17H16N3OS [M + H]
+: 310.1014.
Found: 310.1004.
N-(Benzofuran-5-yl)-2-((4-phenyl-1H-imidazol-2-yl)thio)-
acetamide (24).Compound 41 (36mg, 0.17mmol) was reacted with 4-
phenyl-1H-imidazole-2-thiol (30 mg, 0.17 mmol) according to general
method A. Puriﬁcation by ﬂash chromatography (1−20% v/v MeOH in
DCM) aﬀorded 24 (42 mg, 0.12 mmol, 70% yield) as a white solid. 1H
NMR (500MHz, MeOD) δ 7.87 (d, J = 2.1 Hz, 1H), 7.72 (d, J = 2.2 Hz,
1H), 7.68 (d, J = 7.7 Hz, 2H), 7.46 (br s, 1H), 7.40 (d, J = 8.8 Hz, 1H),
7.37−7.29 (m, 3H), 7.23 (t, J = 7.4 Hz, 1H), 6.76 (dd, J = 2.2, 0.9 Hz,
1H), 3.84 (s, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 169.6, 153.5,
147.4, 140.9, 134.7, 129.8, 129.1, 128.1, 125.8, 118.9, 114.2, 112.1, 107.7,
39.7 ppm. LCMS (ESI−)m/z 348.0 [M−H]−, retention time 1.81 min
(100%). HRMS (ESI+): m/z calculated for C19H16N3O2S [M + H]
+:
350.0963. Found: 350.0971.
N-(4-Iodophenyl)-2-((4-phenyl-1H-imidazol-2-yl)thio)acetamide
(25).Compound 42 (74 mg, 0.25 mmol) was reacted with 4-phenyl-1H-
imidazole-2-thiol (44 mg, 0.25 mmol) according to general method A.
Puriﬁcation by ﬂash chromatography (1−20% v/v MeOH in DCM)
aﬀorded 25 (70 mg, 0.16 mmol, 70% yield) as a white solid. 1H NMR
(500MHz, MeOD) δ 7.66 (d, J = 7.7 Hz, 2H), 7.61−7.54 (m, 2H), 7.44
(br s, 1H), 7.38−7.31 (m, 4H), 7.23 (t, J = 6.7 Hz, 1H), 3.80 (s, 2H)
ppm. 13C NMR (125 MHz, MeOD) δ 169.7, 140.8, 139.6, 138.9, 129.8,
128.2, 125.8, 123.0, 88.1, 39.8 ppm. LCMS (ESI−) m/z 433.9 [M −
H]−, retention time 2.13 min (98%). HRMS (ESI+): m/z calculated for
C17H15IN3OS [M + H]
+: 435.9981. Found: 435.9989.
N-Isopropyl-2-((4-phenyl-1H-imidazol-2-yl)thio)acetamide (26).
A solution of propan-2-amine (22 μL, 0.25 mmol), 2-((4-phenyl-1H-
imidazol-2-yl)thio)acetic acid (60 mg, 0.25 mmol), HATU (194 mg,
0.50 mmol), and DIPEA (90 μL, 0.50 mmol) in EtOAc (10 mL) was
stirred for 5 h at rt. The reaction mixture was diluted with EtOAc (40
mL) and washed with saturated aqueous NaHCO3 (20 mL), water (20
mL), and brine (20 mL). The organic layer was dried over MgSO4 and
ﬁltered. The solvent was removed under reduced pressure to give an oil
residue, which was puriﬁed by ﬂash chromatography (5−100% v/v
EtOAc in petroleum ether) to give the desired product as a white solid
(50 mg, 0.18 mmol, 73% yield).1H NMR (500 MHz, MeOD) δ 7.37 (d,
J = 7.8 Hz, 2H), 7.14 (s, 1H), 7.05 (t, J = 7.7 Hz, 2H), 6.93 (t, J = 7.4 Hz,
1H), 3.62 (dt, J = 13.1, 6.4 Hz, 1H), 3.00 (s, 2H), 0.78 (d, J = 6.6Hz, 6H)
ppm.13C NMR (125 MHz, MeOD) δ 170.3, 141.1, 140.8, 133.7, 129.7,
128.1, 125.7, 119.7, 43.0, 38.8, 22.4 ppm. LCMS (ESI−) m/z 273.9 [M
−H]−, retention time 1.52 min (100%). HRMS (ESI+):m/z calculated
for C14H18N3OS [M + H]
+: 276.1171. Found: 276.1172.
2-((4-(4-Bromophenyl)-1H-imidazol-2-yl)thio)acetic Acid (27).
Following general procedure B, from 4-(4-bromophenyl)-1H-imida-
zole-2-thiol (250 mg, 0.98 mmol) was obtained 27 (220 mg, 0.70 mmol,
72% yield) as a white solid. 1H NMR (400 MHz, MeOD) δ 7.65−7.56
(m, 2H), 7.57−7.39 (m, 3H), 3.80 (s, 2H) ppm. 13C NMR (100 MHz,
MeOD) δ 172.9, 141.9, 140.2, 132.9, 132.6, 127.5, 121.8, 118.9, 37.4
ppm. LCMS (ESI−) m/z 311.0 [M − H]−, retention time 1.59 min
(98%). HRMS (ESI+): m/z calculated for C11H10BrN2O2S [M + H]
+:
312.9646. Found: 312.9654.
2-((4-Phenyl-1H-imidazol-2-yl)thio)acetic Acid (28). Following
general procedure B, from 4-phenyl-1H-imidazole-2-thiol (500 mg,
2.80 mmol) was obtained 28 (450 mg, 1.92 mmol, 69% yield) as a white
solid. 1H NMR (500 MHz, MeOD) δ 7.68 (d, J = 7.2 Hz, 2H), 7.59 (s,
1H), 7.41 (t, J = 7.7 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 3.86 (s, 2H) ppm.
13CNMR (125MHz, MeOD) δ 172.7, 141.7, 139.6, 131.6, 130.0, 129.1,
126.0, 118.9, 37.5 ppm. LCMS (ESI+) m/z 235.1 [M + H]+, retention
time 1.22 min (100%). HRMS (ESI+):m/z calculated for C11H11N2O2S
[M + H]+: 235.0541. Found: 235.0536.
N-(4-(1H-Imidazol-4-yl)phenyl)-2-((4-(4-bromophenyl)-1H-imida-
zol-2-yl)thio)acetamide (29). Compound 43 (40 mg, 0.17 mmol) was
reacted with 4-(4-bromophenyl)-1H-imidazole-2-thiol (43 mg, 0.17
mmol) according to general method A. Puriﬁcation by ﬂash
chromatography (1−20% v/v MeOH in DCM) aﬀorded 29 (51 mg,
0.12 mmol, 69% yield) as a white solid. 1H NMR (400 MHz, MeOD) δ
7.72 (d, J = 1.1 Hz, 1H), 7.66 (d, J = 8.5 Hz, 4H), 7.59−7.47 (m, 5H),
7.40 (br s, 1H), 3.86 (s, 2H) ppm. 13C NMR (125 MHz, MeOD) δ
169.4, 141.2, 138.4, 137.0, 132.8, 127.5, 126.2, 121.4, 116.7, 111.4, 39.7
ppm. LCMS (ESI−) m/z 451.9 [M − H]−, retention time 1.65 min
(100%). HRMS (ESI+): m/z calculated for C20H17BrN5OS [M + H]
+:
454.0337. Found: 454.0334.
1-(4-(1H-Imidazol-4-yl)phenyl)-3-((5-(4-bromophenyl)-1H-imida-
zol-2-yl)methyl)urea (30). To a solution of 4-(1H-imidazol-4-yl)aniline
(50 mg, 0.31 mmol) in THF (5 mL) was added 1,1-carbonyldiimidazole
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(76 mg, 0.47 mmol). The mixture was stirred at rt overnight, and then it
was ﬁltered. The ﬁlter was washed with THF (2 × 3 mL) and the
resulting solid (30 mg, 0.12 mmol) was dissolved in DMF (3 mL), and
44 (42 mg, 0.12 mmol) and N,N-diisopropylethylamine (74 μL, 0.48
mmol) were added. The reaction mixture was stirred at rt for 14 h, and
then it was poured into water, extracted with EtOAc, dried over Na2SO4,
and concentrated. After cooling to 0 °C, a 1:5 v/v mixture of MeOH and
DCM (12 mL) was added and the suspended solid was collected by
ﬁltration and dried at vacuum to yield 30 (35 mg, 0.08 mmol, 26% yield)
as a white solid. 1HNMR (500MHz, DMSO-d6) δ 12.03 (br s, 2H), 8.64
(br s, 1H), 7.73−7.68 (m, 2H), 7.64−7.59 (m, 2H), 7.57 (d, J = 1.9 Hz,
1H), 7.52−7.47 (m, 2H), 7.47−7.39 (m, 2H), 7.39−7.32 (m, 2H), 6.58
(br s, 1H), 4.33 (d, J = 5.5 Hz, 2H) ppm. 13C NMR (125 MHz, DMSO-
d6) δ 155.5, 146.9, 140.6, 138.9, 138.9, 135.9, 134.6, 131.7, 128.8, 126.6,
125.1, 125.0, 119.0, 118.4, 118.2, 113.7, 111.7, 37.6 ppm. LCMS (ESI−)
m/z 437.0 [M − H]−, retention time 5.07 min (97%). HRMS (ESI+):
m/z calculated for C20H18BrN6O [M + H]
+: 437.0725. Found:
437.0725.
N-(4-(4-Bromophenyl)-1H-imidazol-2-yl)-2-(4-(1-methyl-1H-imi-
dazol-4-yl)phenoxy)propanamide (31). 4-(4-Bromophenyl)-1H-imi-
dazol-2-amine 50 (48mg, 0.20mmol) was reacted with the acid chloride
60 (53 mg, 0.20 mmol) and Et3N (112 μL, 0.80 mmol) according to
general method C. The crude product was puriﬁed by ﬂash
chromatography (0−20% v/v MeOH in DCM) to give compound 31
as a white solid (64 mg, 0.14 mmol, 67% yield). 1H NMR (500 MHz,
CDCl3) δ 10.79 (br s, 1H), 9.49 (br s, 1H), 7.69 (d, J = 8.7 Hz, 2H),
7.58−7.41 (m, 5H), 7.18−6.97 (m, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.86
(d, J = 6.8 Hz, 1H), 3.71 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H) ppm. 13CNMR
(125 MHz, CDCl3) δ 171.5, 155.2, 141.8, 141.2, 138.0, 137.2, 131.7,
129.1, 127.6, 126.3, 120.5, 115.8, 115.6, 115.3, 108.1, 74.6, 33.5, 18.5
ppm. LCMS (ESI+) m/z 465.9 [M + H]+, retention time 2.73 min
(95%). HRMS (ESI+): m/z calculated for C22H21BrN5O2 [M + H]
+:
466.0879. Found: 466.0874. ((S)-31): 69% yield. [α]D
25 −40.2 (c 1.0,
CHCl3). LCMS (ESI+) m/z 466.0 [M + H]
+, retention time 2.70 min
(95%). HRMS (ESI+): m/z calculated for C22H21BrN5O2 [M + H]
+:
466.0879. Found: 466.0879.
N-(4-(1H-Imidazol-4-yl)phenyl)-2-((4-phenyl-1H-imidazol-2-yl)-
thio)acetamide (32). Compound 43 (40 mg, 0.17 mmol) was reacted
with 4-(4-bromophenyl)-1H-imidazole-2-thiol (30 mg, 0.17 mmol)
according to general method A. Puriﬁcation by ﬂash chromatography
(1−20% v/v MeOH in DCM) aﬀorded 32 (41 mg, 0.11 mmol, 65%
yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.46 (br s,
2H), 10.42 (br s, 1H), 7.76 (br s, 2H), 7.68 (d, J = 8.2 Hz, 4H), 7.56 (d, J
= 8.5 Hz, 2H), 7.52 (s, 1H), 7.34 (br s, 2H), 7.19 (br s, 1H), 3.99 (s, 2H)
ppm. 13C NMR (125 MHz, DMSO-d6) δ 167.0, 141.7, 139.9, 137.7,
136.2, 134.6, 128.9, 126.7, 125.2, 124.6, 119.7, 115.4, 39.5 ppm. LCMS
(ESI+) m/z 376.1 [M + H]+, retention time 0.88 min (100%). HRMS
(ESI+): m/z calculated for C20H18N5OS [M + H]
+: 376.1232. Found:
376.1241.
N-(4-(4-Bromophenyl)oxazol-2-yl)-2-(4-(1-methyl-1H-imidazol-4-
yl)phenoxy)propanamide (33). 4-(4-Bromophenyl)oxazol-2-amine 61
(39 mg, 0.16 mmol) was reacted with the acid chloride 60 (43 mg, 0.16
mmol) and Et3N (90 μL, 0.64 mmol) according to general method C.
The crude product was puriﬁed by ﬂash chromatography (0−15% v/v
MeOH in DCM) to give compound 33 as a white solid (49 mg, 0.10
mmol, 64% yield). 1H NMR (400 MHz, CDCl3) δ 9.13 (br s, 1H),
7.81−7.66 (m, 3H), 7.63−7.50 (m, 4H), 7.47 (s, 1H), 7.13 (d, J = 1.3
Hz, 1H), 7.03−6.94 (m, 2H), 4.90 (q, J = 6.6 Hz, 1H), 3.74 (s, 3H), 1.70
(d, J = 6.8 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 155.1, 141.7,
138.0, 131.9, 131.7, 130.3, 129.4, 129.3, 127.8, 127.0, 126.7, 126.4, 122.2,
116.0, 115.4, 75.1, 33.5, 18.4 ppm. LCMS (ESI+) m/z 468.9 [M + H]+,
retention time 2.86 min (95%). HRMS (ESI+): m/z calculated for
C22H20BrN4O3 [M + H]
+: 467.0719. Found: 467.0711.
2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)-N-phenylpropana-
mide (34). Aniline (28 μL, 0.30 mmol) was reacted with the acid
chloride 60 (53 mg, 0.20 mmol) and Et3N (112 μL, 0.80 mmol)
according to general method D. The crude product was puriﬁed by ﬂash
chromatography (0−20% v/vMeOH in DCM) to give compound 34 as
a white solid (48 mg, 0.14 mmol, 74% yield). 1H NMR (400 MHz,
CDCl3) δ 8.25 (br s, 1H), 7.79−7.69 (m, 2H), 7.60−7.52 (m, 2H), 7.47
(d, J = 1.3 Hz, 1H), 7.35 (dd, J = 8.5, 7.3 Hz, 2H), 7.19−7.06 (m, 2H),
7.05−6.97 (m, 2H), 4.82 (q, J = 6.7Hz, 1H), 3.73 (s, 3H), 1.69 (d, J = 6.8
Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 170.3, 155.6, 141.8,
137.9, 137.0, 129.0, 129.0, 126.3, 124.7, 120.0, 116.0, 115.3, 75.6, 33.5,
18.7 ppm. LCMS (ESI+) m/z 322.2 [M + H]+, retention time 1.86 min
(97%). HRMS (ESI+): m/z calculated for C19H20N3O2 [M + H]
+:
322.1556. Found: 322.1552.
N-(4-Iodophenyl)-2-(4-(1-methyl-1H-imidazol-4-yl)phenoxy)-
propanamide (35). 4-Iodoaniline (65 mg, 0.30 mmol) was reacted with
the acid chloride 60 (53 mg, 0.20 mmol) and Et3N (112 μL, 0.80 mmol)
according to the general method D. The crude product was puriﬁed by
ﬂash chromatography (0−20% v/v MeOH in DCM) to give compound
35 as a pink solid (62 mg, 0.14 mmol, 68% yield). 1H NMR (400 MHz,
CDCl3) δ 8.28 (br s, 1H), 7.77−7.69 (m, 2H), 7.69−7.57 (m, 2H), 7.47
(d, J = 1.4 Hz, 1H), 7.41−7.31 (m, 2H), 7.11 (d, J = 1.3 Hz, 1H), 7.03−
6.91 (m, 2H), 4.80 (q, J = 6.7 Hz, 1H), 3.73 (s, 3H), 1.67 (d, J = 6.8 Hz,
3H) ppm. 13C NMR (100 MHz, CDCl3) δ 170.4, 155.5, 141.7, 137.9,
136.9, 129.0, 126.3, 126.0, 121.8, 116.0, 115.3, 87.9, 75.6, 33.5, 18.6 ppm.
LCMS (ESI+) m/z 448.2 [M + H]+, retention time 2.47 min (96%).
HRMS (ESI+): m/z calculated for C19H19IN3O2 [M + H]
+: 448.0522.
Found: 448.0517.
2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)-N-(4-phenyl-1H-imi-
dazol-2-yl)propanamide (36). 4-Phenyl-1H-imidazol-2-amine 51 (33
mg, 0.20 mmol) was reacted with the acid chloride 60 (53 mg, 0.20
mmol) and Et3N (112 μL, 0.80 mmol) according to general method C.
The crude product was puriﬁed by ﬂash chromatography (0−15% v/v
MeOH in DCM) to give compound 36 as a brown solid (57 mg, 0.15
mmol, 72% yield). 1HNMR (400MHz, CDCl3) δ 10.84 (br s, 1H), 9.51
(br s, 1H), 7.78−7.56 (m, 4H), 7.46 (d, J = 1.2 Hz, 1H), 7.39 (t, J = 7.7
Hz, 2H), 7.22−7.26 (m, 1H), 7.14 (s, 1H), 7.11 (d, J = 1.4 Hz, 1H),
7.02−6.89 (m, 2H), 4.89 (q, J = 6.8Hz, 1H), 3.73 (s, 3H), 1.68 (d, J = 6.8
Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 171.3, 155.2, 141.8,
137.9, 129.1, 128.7, 126.9, 126.3, 124.6, 115.9, 115.3, 107.8, 74.5, 33.5,
18.5 ppm. LCMS (ESI+) m/z 388.1 [M + H]+, retention time 4.44 min
(100%). HRMS (ESI+): m/z calculated for C22H22N5O2 [M + H]
+:
388.1773. Found: 388.1767.
2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)-N-(4-(4-morpholino-
phenyl)-1H-imidazol-2-yl)propanamide (37). 4-(4-Morpholinophen-
yl)-1H-imidazol-2-amine 52 (40 mg, 0.16 mmol) was reacted with the
acid chloride 60 (43 mg, 0.16 mmol) and Et3N (90 μL, 0.65 mmol)
according to general method C. The crude product was puriﬁed by ﬂash
chromatography (3−15% v/vMeOH in DCM) to give compound 37 as
a brown solid (51 mg, 0.11 mmol, 67% yield). 1H NMR (400 MHz,
CDCl3) δ 10.74 (br s, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.54 (br s, 2H), 7.47
(d, J = 1.4 Hz, 1H), 7.11 (d, J = 1.4 Hz, 1H), 7.03−6.88 (m, 5H), 4.90 (q,
J = 6.7 Hz, 1H), 4.06−3.83 (m, 4H), 3.73 (s, 3H), 3.27−3.01 (m, 4H),
1.69 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 171.5,
155.3, 150.3, 141.8, 141.0, 137.9, 137.8, 128.9, 126.3, 125.5, 115.8, 115.3,
74.4, 66.9, 49.3, 33.6, 18.7 ppm. LCMS (ESI+) m/z 473.2 [M + H]+,
retention time 2.22 min (100%). HRMS (ESI+): m/z calculated for
C26H29N6O3 [M + H]
+: 473.2301. Found: 473.2297.
N-(4-(4-Methoxyphenyl)-1H-imidazol-2-yl)-2-(4-(1-methyl-1H-
imidazol-4-yl)phenoxy)propanamide (38). 4-(4-Methoxyphenyl)-
1H-imidazol-2-amine 53 (30 mg, 0.16 mmol) was reacted with the
acid chloride 60 (43 mg, 0.16 mmol) and Et3N (90 μL, 0.65 mmol)
according to general method C. The crude product was puriﬁed by ﬂash
chromatography (1−20% v/vMeOH in DCM) to give compound 38 as
a yellow solid (45 mg, 0.11 mmol, 67% yield). 1H NMR (400 MHz,
CDCl3) δ 10.73 (br s, 1H), 9.62 (br s, 1H), 7.78−7.65 (m, 2H), 7.57 (br
s, 2H), 7.46 (d, J = 1.4 Hz, 1H), 7.10 (d, J = 1.3 Hz, 1H), 7.02 (s, 1H),
6.95 (dd, J = 10.5, 8.8 Hz, 4H), 4.88 (q, J = 6.8 Hz, 1H), 3.84 (s, 3H),
3.73 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (125 MHz,
CDCl3) δ 171.4, 158.7, 155.3, 141.8, 140.8, 137.9, 129.1, 126.3, 125.8,
115.8, 115.3, 114.2, 74.7, 55.3, 33.4, 18.4 ppm. LCMS (ESI+)m/z 418.3
[M + H]+, retention time 4.69 min (100%). HRMS (ESI+): m/z
calculated for C23H24N5O3 [M + H]
+: 418.1879. Found: 418.1875.
N-(4-(4-Iodophenyl)-1H-imidazol-2-yl)-2-(4-(1-methyl-1H-imida-
zol-4-yl)phenoxy)propanamide (39). 4-(4-Iodophenyl)-1H-imidazol-
2-amine 54 (46 mg, 0.16 mmol) was reacted with the acid chloride 60
(43 mg, 0.16 mmol) and Et3N (90 μL, 0.65 mmol) according to general
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method C. The crude product was puriﬁed by ﬂash chromatography
(1−20% v/v MeOH in DCM) to give compound 39 as a yellow solid
(50 mg, 0.10 mmol, 61% yield). 1H NMR (500 MHz, CDCl3) δ 10.75
(br s, 1H), 9.42 (br s, 1H), 7.69 (t, J = 8.3 Hz, 4H), 7.53−7.33 (m, 3H),
7.10 (d, J = 8.3 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4.88 (q, J = 6.7 Hz,
1H), 3.71 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H) ppm. 13C NMR (125 MHz,
CDCl3) δ 171.5, 155.2, 141.7, 138.0, 137.7, 129.1, 126.5, 126.3, 115.8,
115.3, 108.1, 91.8, 74.5, 33.5, 18.5 ppm. LCMS (ESI+) m/z 514.2 [M +
H]+, retention time 4.61 min (95%). HRMS (ESI+): m/z calculated for
C22H21IN5O2 [M + H]
+: 514.0740. Found: 514.0740.
2-Chloro-N-phenylacetamide (40). Aniline (400 μL, 4.38 mmol)
was reacted with chloroacetyl chloride (380 μL, 4.77 mmol) and Et3N
(670 μL, 4.77 mmol) according to general method E, and used in
subsequent reactions without further puriﬁcation. Compound 40 was
obtained (720 mg, 4.24 mmol, 96% yield) as a green solid and was used
without further puriﬁcation. 1H NMR (400 MHz, CDCl3) δ 8.27 (br s,
1H), 7.58 (d, J = 7.7 Hz, 2H), 7.39 (t, J = 7.9 Hz, 2H), 7.20 (t, J = 7.4 Hz,
1H), 4.22 (s, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ 163.9, 136.8,
129.3, 125.4, 120.2, 43.0 ppm. LCMS (ESI+) m/z 170.1 [M + H]+,
retention time 1.58 min (100%). HRMS (ESI+): m/z calculated for
C8H9ClNO [M + H]
+: 170.0373. Found: 170.0366. NMR data is in
accordance with literature values.39
N-(Benzofuran-5-yl)-2-chloroacetamide (41). Benzofuran-5-amine
(140 mg, 1.05 mmol) was reacted with chloroacetyl chloride (93 μL,
1.16 mmol) and Et3N (162 μL, 1.16 mmol) according to general
method E, and it was used in subsequent reactions without further
puriﬁcation. Compound 41 was obtained (219 mg, 1.04 mmol, 99%
yield) as a green solid and was used without further puriﬁcation. 1H
NMR (400 MHz, CDCl3) δ 8.41 (br s, 1H), 7.94 (d, J = 2.2 Hz, 1H),
7.64 (d, J = 2.2 Hz, 1H), 7.47 (dd, J = 8.8, 0.8 Hz, 1H), 7.32 (dd, J = 8.8,
2.2 Hz, 1H), 6.76 (dd, J = 2.2, 0.9 Hz, 1H), 4.23 (s, 2H) ppm. 13C NMR
(100 MHz, CDCl3) δ 163.9, 152.4, 146.1, 131.9, 127.9, 117.7, 113.3,
111.6, 106.8, 43.0 ppm. LCMS (ESI+) m/z 210.1 [M + H]+, retention
time 1.71 min (100%). HRMS (ESI+):m/z calculated for C11H9ClNO2
[M + H]+: 210.0322. Found: 210.0319.
2-Chloro-N-(4-iodophenyl)acetamide (42). 4-Iodoaniline (500 mg,
2.28 mmol) was reacted with chloroacetyl chloride (200 μL, 2.51 mmol)
and Et3N (350 μL, 2.51 mmol) according to general method E. The
crude product was puriﬁed by ﬂash chromatography (10−100% v/v
EtOAc in petroleum ether) to give compound 42 as a brown solid (600
mg, 2.03 mmol, 89% yield). 1H NMR (400 MHz, CDCl3) δ 8.32−8.11
(br s, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 4.20 (s, 2H)
ppm. 13C NMR (100 MHz, CDCl3) δ 163.8, 138.1, 136.4, 121.8, 88.7,
42.9 ppm. LCMS (ESI−)m/z 293.7 [M−H]−, retention time 2.38 min
(100%). HRMS (ESI−): m/z calculated for C8H6ClINO [M − H]−:
293.9183. Found: 293.9187. NMR data is in accordance with literature
values.40
N-(4-(1H-Imidazol-4-yl)phenyl)-2-chloroacetamide (43). 4-(1H-
Imidazol-4-yl)aniline (200 mg, 1.25 mmol) was reacted with
chloroacetyl chloride (109 μL, 1.38 mmol) and Et3N (192 μL, 1.38
mmol) according to general method E. The crude product was puriﬁed
by ﬂash chromatography (3−20% v/v MeOH in DCM) to give
compound 43 as a yellow solid (264 mg, 1.12 mmol, 89% yield). 1H
NMR (400 MHz, DMSO-d6) δ 10.43 (br s, 1H), 9.83 (br s, 1H), 7.98
(br s, 1H), 7.77−7.65 (m, 2H), 7.70−7.47 (m, 3H), 4.27 (s, 2H) ppm.
LCMS (ESI+) m/z 236.2 [M + H]+, retention time 1.15 min (100%).
HRMS (ESI+): m/z calculated for C11H10ClN3O [M + H]
+: 236.0591.
Found: 236.0590.
(5-(4-Bromophenyl)-1H-imidazol-2-yl)methanamine Hydrochlor-
ide (44). 4 M HCl (2 mL) was added slowly to a stirred solution of
benzyl ((5-(4-bromophenyl)-1H-imidazol-2-yl)methyl)carbamate36
(105 mg, 0.26 mmol) in dioxane (1 mL). The mixture was stirred at
100 °C for 4 h, and then the solvents were removed under reduced
pressure to give the desired product as a white solid (86 mg, 0.26 mmol,
100% yield). 1H NMR (500 MHz, MeOD) δ 8.00 (s, 1H), 7.75−7.67
(m, 4H), 4.55 (s, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 140.8,
136.0, 133.7, 128.4, 127.6, 124.7, 117.8, 111.4, 34.8 ppm. LCMS (ESI−)
m/z 250.1 [M −H]−, retention time 2.13 min (100%). HRMS (ESI−):
m/z calculated for C10H9BrN3 [M + H]
+: 249.9980. Found: 249.9987.
N-(4-(4-Bromophenyl)-1H-imidazol-2-yl)acetamide (45). Follow-
ing general method F, from 2-bromo-1-(4-bromophenyl)ethanone (104
mg, 0.38 mmol) was obtained 45 (88 mg, 0.31 mmol, 84% yield) as a
green solid. 1H NMR (500 MHz, DMSO-d6) δ 11.66 (br s, 1H), 11.20
(br s, 1H), 7.72−7.57 (m, 2H), 7.54−7.42 (m, 2H), 7.30 (d, J = 1.6 Hz,
1H), 2.05 (s, 3H) ppm. 13CNMR (125MHz, DMSO-d6) δ 169.0, 141.9,
135.5, 134.4, 131.7, 126.4, 119.0, 110.4, 23.3 ppm. LCMS (ESI+) m/z
282.1 [M + H]+, retention time 2.13 min (100%). HRMS (ESI+): m/z
calculated for C11H11BrN3O [M + H]
+: 280.0085. Found: 280.0080.
NMR data is in accordance with literature values.37
N-(4-Phenyl-1H-imidazol-2-yl)acetamide (46). Following general
method F, from 2-bromo-1-phenylethan-1-one (100 mg, 0.50 mmol)
was obtained 46 (79 mg, 0.39 mmol, 78% yield) as a green solid. 1H
NMR (400 MHz, DMSO-d6) δ 11.59 (br s, 1H), 11.24 (br s, 1H), 7.71
(d, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.25 (br s, 1H), 7.16 (t, J =
7.4 Hz, 1H), 2.07 (s, 3H) ppm.13C NMR (100 MHz, DMSO-d6) δ
169.0, 141.7, 136.6, 128.9, 126.3, 124.4, 109.6, 23.3 ppm. LCMS (ESI−)
m/z 200.0 [M − H]−, retention time 1.44 min (100%). HRMS (ESI+):
m/z calculated for C11H12N3O [M + H]
+: 202.0980. Found: 202.0977.
NMR data is in accordance with literature values.37
N-(4-(4-Morpholinophenyl)-1H-imidazol-2-yl)acetamide (47).
Following general method F, from 2-bromo-1-(4-(piperidin-1-yl)-
phenyl)ethan-1-one (106 mg, 0.38 mmol) was obtained 47 (90 mg,
0.31 mmol, 83% yield) as a brown solid. 1H NMR (500 MHz, DMSO-
d6) δ 11.46 (br s, 1H), 11.17 (br s, 1H), 7.55 (d, J = 8.2 Hz, 2H), 7.06 (br
s, 1H), 6.89 (d, J = 8.5 Hz, 2H), 3.93−3.53 (m, 4H), 3.07 (t, J = 4.8 Hz,
4H), 2.04 (s, 3H) ppm.13C NMR (125MHz, DMSO-d6) δ 168.8, 149.8,
141.4, 136.8, 125.2, 115.6, 113.5, 107.9, 66.6, 49.0, 23.2 ppm. LCMS
(ESI−) m/z 285.1 [M − H]−, retention time 1.60 min (95%). HRMS
(ESI+): m/z calculated for C15H19N4O2 [M + H]
+: 287.1508. Found:
287.1505.
N-(4-(4-Methoxyphenyl)-1H-imidazol-2-yl)acetamide (48). Fol-
lowing general method F, from 2-bromo-1-(4-methoxyphenyl)ethan-
1-one (150 mg, 0.66 mmol) was obtained 48 (110 mg, 0.47 mmol, 71%
yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 11.52 (br s,
1H), 11.20 (br s, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.11 (s, 1H), 6.89 (d, J =
8.4 Hz, 2H), 3.75 (s, 3H), 2.06 (s, 3H) ppm. 13C NMR (100 MHz,
DMSO-d6) δ 168.5, 157.8, 141.2, 136.1, 127.6, 125.3, 113.9, 107.9, 55.1,
22.9 ppm. LCMS (ESI−)m/z 230.1 [M−H]−, retention time 1.52 min
(96%). HRMS (ESI+): m/z calculated for C12H14N3O2 [M + H]
+:
232.1086. Found: 232.1082. NMR data is in accordance with literature
values.37
N-(4-(4-Iodophenyl)-1H-imidazol-2-yl)acetamide (49). Following
general method F, from 2-bromo-1-(4-iodophenyl)ethan-1-one (214
mg, 0.66 mmol) was obtained 49 (190 mg, 0.58 mmol, 88% yield) as a
green solid. 1H NMR (500 MHz, DMSO-d6) δ 11.66 (br s, 1H), 11.21
(br s, 1H), 7.64 (d, J = 8.1Hz, 2H), 7.51 (d, J = 8.1Hz, 2H), 7.30 (s, 1H),
2.05 (s, 3H) ppm. 13C NMR (125 MHz, DMSO-d6) δ 168.5, 141.4,
137.1, 135.1, 134.3, 126.2, 109.9, 90.9, 22.8. LCMS (ESI−) m/z 326.0
[M − H]−, retention time 2.43 min (100%). HRMS (ESI+): m/z
calculated for C11H11IN3O [M + H]
+: 327.9947. Found: 327.9945.
4-(4-Bromophenyl)-1H-imidazol-2-amine (50). Following general
method G, from N-(4-(4-bromophenyl)-1H-imidazol-2-yl)acetamide
45 (88 mg, 0.31 mmol) was obtained 50 (70 mg, 0.29 mmol, 95% yield)
as a brown solid.1H NMR (500 MHz, DMSO-d6) δ 7.52 (d, J = 8.1 Hz,
2H), 7.42 (d, J = 8.6 Hz, 2H), 7.04 (s, 1H), 5.40 (br s, 2H) ppm. 13C
NMR (125 MHz, DMSO-d6) δ 150.4, 134.0, 131.2, 126.0, 125.4, 117.5,
110.5 ppm. LCMS (ESI+)m/z 240.1 [M +H]+, retention time 1.50 min
(97%). HRMS (ESI+): m/z calculated for C9H9BrN3 [M + H]
+:
237.9980. Found: 237.9980. NMR data is in accordance with literature
values.37
4-Phenyl-1H-imidazol-2-amine (51). Following general method G,
from N-(4-phenyl-1H-imidazol-2-yl)acetamide 46 (70 mg, 0.35 mmol)
was obtained 51 (47 mg, 0.29 mmol, 84% yield) as a red solid. 1H NMR
(400 MHz, MeOD) δ 7.62−7.46 (m, 2H), 7.31 (t, J = 7.7 Hz, 2H), 7.16
(td, J = 7.5, 1.2 Hz, 1H), 6.91 (s, 1H) ppm.13C NMR (125 MHz,
MeOD) δ 150.3, 132.9, 128.4, 128.1, 125.6, 123.5, 111.2 ppm. LCMS
(ESI+) m/z 160.1 [M + H]+, retention time 1.45 min (100%). HRMS
(ESI+): m/z calculated for C9H10BrN3 [M + H]
+: 160.0875. Found:
160.0873. NMR data is in accordance with literature values.37
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4-(4-Morpholinophenyl)-1H-imidazol-2-amine (52). Following
general method G, from N-(4-(4-morpholinophenyl)-1H-imidazol-2-
yl)acetamide 47 (85 mg, 0.30 mmol) was obtained 52 (60 mg, 0.24
mmol, 82% yield) as a brown solid. 1H NMR (400MHz, MeOD) δ 7.47
(d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 6.78 (s, 1H), 3.91−3.64 (m,
4H), 3.19−3.02 (m, 4H) ppm. 13C NMR (125 MHz, MeOD) δ 149.9,
149.8, 129.3, 125.0, 124.5, 115.8, 113.0, 66.6, 49.4 ppm. LCMS (ESI+)
m/z 245.1 [M + H]+, retention time 1.50 min (100%). HRMS (ESI+):
m/z calculated for C13H17N4O [M + H]
+: 245.1402. Found: 245.1390.
4-(4-Methoxyphenyl)-1H-imidazol-2-amine (53). Following gen-
eral method G, from N-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-
acetamide 48 (83 mg, 0.36 mmol) was obtained 53 (65 mg, 0.34
mmol, 95% yield) as a brown solid. 1H NMR (400 MHz, MeOD) δ
7.54−7.39 (m, 2H), 7.04−6.85 (m, 2H), 6.78 (s, 1H), 3.81 (s, 3H) ppm.
13C NMR (100MHz, MeOD) δ 158.3, 150.0, 125.9, 125.0, 124.8, 113.6,
109.8, 54.3 ppm. LCMS (ESI+) m/z 190.2 [M + H]+, retention time
1.61 min (100%). HRMS (ESI+): m/z calculated for C10H12N3O [M +
H]+: 190.0980. Found: 190.0979. NMR data is in accordance with
literature values.37
4-(4-Iodophenyl)-1H-imidazol-2-amine (54). Following general
method G, from N-(4-(4-iodophenyl)-1H-imidazol-2-yl)acetamide 49
(150 mg, 0.46 mmol) was obtained 54 (103 mg, 0.36 mmol, 79% yield)
as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 7.58 (d, J = 8.3 Hz,
2H), 7.38 (d, J = 8.2 Hz, 2H), 7.03 (s, 1H), 5.35 (br s, 2H) ppm. 13C
NMR (125 MHz, DMSO-d6) δ 150.8, 137.4, 134.6, 133.4, 126.0, 111.1,
90.2 ppm. LCMS (ESI+) m/z 286.1 [M + H]+, retention time 2.09 min
(100%). HRMS (ESI+): m/z calculated for C9H9IN3 [M + H]
+:
285.9841. Found: 285.9846.
4-(1H-Imidazol-4-yl)phenol (55). 2-Bromo-1-(4-hydroxyphenyl)-
ethan-1-one (1.0 g, 4.67 mmol) was dissolved in formamide (5 mL),
and the reaction mixture was heated at 150 °C for 24 h. After cooling to
rt, the resulting mixture was diluted with EtOAc (40 mL) and washed
with saturated aqueous NaHCO3 (40 mL). The aqueous layer was
extracted with EtOAc (2 × 40 mL), and the combined organic layers
were dried over MgSO4, ﬁltered, and concentrated to give 55 (0.75 g,
4.67 mmol, 99% yield) as a brown oil. 1H NMR (400 MHz, MeOD) δ
8.17 (br s, 1H), 7.68 (d, J = 1.2 Hz, 1H), 7.64−7.44 (m, 2H), 7.25 (d, J =
1.1Hz, 1H), 6.82 (d, J = 8.6Hz, 2H) ppm.13CNMR (100MHz,MeOD)
δ 156.3, 135.1, 125.8, 124.3, 115.1 ppm. LCMS (ESI+) m/z 161.2 [M +
H]+, retention time 0.54min (100%). HRMS (ESI+):m/z calculated for
C9H9N2O [M + H]
+: 161.0715. Found: 161.0720. NMR data is in
accordance with literature values.38
4-(4-Methoxyphenyl)-1-methyl-1H-imidazole (56). To a solution
of 55 (2.77 g, 17 mmol) in DMF (20 mL) containing cesium carbonate
(12.4 g, 38mmol) at rt was added iodomethane (2.4 mL, 38mmol). The
reaction mixture was stirred at rt for 8 h. The reaction mixture was then
cooled to 0 °C and quenched with H2O (70 mL) and extracted with
EtOAc (3 × 60 mL). The combined organic layers were washed with
brine (3 × 100 mL), dried over MgSO4, ﬁltered, and concentrated to
give 56 (2.8 g, 15 mmol, 88% yield) as a brown solid. 1H NMR (400
MHz, CDCl3) δ 7.71 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 1.3 Hz, 1H), 7.10
(d, J = 1.4 Hz, 1H), 6.94 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H), 3.73 (s, 3H)
ppm. 13C NMR (100 MHz, CDCl3) δ 158.6, 142.4, 137.8, 127.2, 126.0,
114.8, 114.0, 55.3, 33.5. LCMS (ESI+) m/z 189.2 [M + H]+, retention
time 1.38 min (100%). HRMS (ESI+): m/z calculated for C11H13N2O
[M +H]+: 189.1028. Found: 189.1031. NMR data is in accordance with
literature values.41
4-(1-Methyl-1H-imidazol-4-yl)phenol (57). A solution of 4-(4-
methoxyphenyl)-1-methyl-1H-imidazole 56 (1.21 g, 6.42 mmol) in
anhydrous DCM (30 mL) at −78 °C was treated with BBr3 (16 mL,
16.05 mmol, 1 M in DCM). The reaction mixture was stirred at −78 °C
for 10min and 2 h at rt. The reaction mixture was then cooled to−78 °C
and quenched with MeOH (4 mL). The solvents were then removed
under reduced pressure, and the crude product was redissolved in
EtOAc (50 mL) and washed with saturated NaHCO3 solution. The
aqueous phase was extracted with EtOAc (2 × 50 mL), and the
combined organic fractions were dried with anhydrous MgSO4 and
ﬁltered oﬀ, and the solvent was removed under vacuum to give 57 (1.30
g, 6.17 mmol, 96% yield) as a brown solid, which was used in the next
step without further puriﬁcation. 1H NMR (400 MHz, MeOD) δ 8.99−
8.80 (m, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 6.93 (d, J
= 8.8 Hz, 2H), 3.99 (s, 3H) ppm. 13CNMR (100MHz, MeOD) δ 159.1,
135.1, 134.6, 126.9, 117.3, 117.2, 115.8, 35.0 ppm. LCMS (ESI+) m/z
175.1 [M + H]+, retention time 1.09 min (100%). HRMS (ESI+): m/z
calculated for C10H11N2O [M + H]
+: 175.0871. Found: 175.0870.
Methyl 2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)propanoate
(58). Cs2CO3 (3.46 g, 10.62 mmol) and methyl 2-bromopropanoate
(1.29 g, 6.81 mmol) were added to a solution of phenol derivative 57
(1.12 g, 5.32 mmol) in anhydrous DMF (10 mL), and the mixture was
stirred at rt for 1 h and at 60 °C for 5 h. After cooling to rt, the reaction
was diluted with water (80 mL) and extracted with EtOAc (2 × 80 mL).
The combined organic layers were washed with brine (3 × 100 mL),
dried over MgSO4, ﬁltered, and concentrated. The crude product was
puriﬁed by ﬂash chromatography (0−20% v/v MeOH in DCM) to give
58 (1.30 g, 4.99 mmol, 92% yield) as an orange oil. 1H NMR (400MHz,
CDCl3) δ 7.74−7.61 (m, 2H), 7.45 (d, J = 1.3 Hz, 1H), 7.08 (d, J = 1.4
Hz, 1H), 6.96−6.81 (m, 2H), 4.81 (q, J = 6.8 Hz, 1H), 3.77 (s, 3H), 3.71
(s, 3H), 1.64 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ
172.8, 156.5, 142.1, 137.8, 128.1, 126.0, 115.3, 115.1, 72.7, 52.3, 33.5,
18.6 ppm. LCMS (ESI+) m/z 261.3 [M + H]+, retention time 1.50 min
(100%). HRMS (ESI+): m/z calculated for C14H17N2O3 [M + H]
+:
261.1239. Found: 261.1232.
2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)propanoic Acid (59).
Methyl 2-(4-(1-methyl-1H-imidazol-4-yl)phenoxy)propanoate 58
(0.53 g, 2.04 mmol) was dissolved in a 2:1 v/v mixture of THF and
H2O (7.5 mL), and then NaOH (0.16 g, 4.08 mmol) was added. The
reaction mixture was heated at 80 °C for 40 min. After the reaction
mixture was allowed to cool to rt, the solvents were removed. The
mixture was then diluted with H2O (5 mL) and acidiﬁed to pH 7−8
using 1 N HCl. The mixture was cooled, and the resulting precipitate
was collected by ﬁltration, washed with water (2× 3 mL) and petroleum
ether (2× 3mL), and dried in vacuo to aﬀord acid 59 (0.33 g, 1.33mmol,
65% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.69−
7.55 (m, 3H), 7.46 (d, J = 1.3 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 4.81 (q, J
= 6.8 Hz, 1H), 3.66 (s, 3H), 1.49 (d, J = 6.7 Hz, 3H). 13C NMR (100
MHz, DMSO-d6) δ 173.3, 156.1, 140.4, 138.2, 127.8, 125.4, 115.8,
114.8, 71.7, 33.1, 18.4. LCMS (ESI+) m/z 247.2 [M + H]+, retention
time 1.43 min (100%). HRMS (ESI+): m/z calculated for C13H15N2O3
[M + H]+: 247.1083. Found: 247.1080.
(S)-2-(4-(1-Methyl-1H-imidazol-4-yl)phenoxy)propanoic Acid ((S)-
59). To a solution of 57 (212 mg, 1.21 mmol) in anhydrous THF (5
mL) was added ethyl D-lactate (215 mg, 1.82 mmol). After the reaction
mixture was cooled to 0 °C, PPh3 (478mg, 1.82 mmol) and DEAD (286
μL, 1.82 mmol) were added, and the reaction mixture was stirred for 16
h at rt. The reaction mixture was poured into ice−water (40 mL) and
extracted with DCM (3 × 50 mL). The combined organic layers were
washed with brine, dried over anhydrous MgSO4, ﬁltered, and
concentrated. The crude product was puriﬁed by ﬂash chromatography
(0−15% v/v MeOH in DCM) to give ethyl (S)-2-(4-(1-methyl-1H-
imidazol-4-yl)phenoxy)propanoate as an orange solid. LCMS (ESI+)
m/z 275.3 [M +H]+, retention time 2.06 min (94%). Ethyl (S)-2-(4-(1-
methyl-1H-imidazol-4-yl)phenoxy)propanoate (200 mg, 0.73 mmol)
was dissolved in a 2:1 v/v mixture of THF and H2O (7.5 mL), and then
NaOH (58mg, 1.46 mmol) was added. The reaction mixture was stirred
at rt for 3 h, and the solvents were removed. The residue was dissolved in
EtOAc (40 mL) and then extracted with H2O (40 mL). The aqueous
layer was acidiﬁed to pH 7−8 using 1 N HCl. The mixture was cooled,
and the resulting precipitate was collected by ﬁltration, washed with
water (2× 3 mL) and petroleum ether (2× 3 mL), and dried in vacuo to
aﬀord acid (S)-59 (100mg, 0.40mmol, 56% yield) as a white solid. [α]D
25
−51.6 (c 1.0, CHCl3). LCMS (ESI+) m/z 247.2 [M + H]+, retention
time 1.43 min (100%). HRMS (ESI+): m/z calculated for C13H15N2O3
[M + H]+: 247.1083. Found: 247.1079.
4-(4-Bromophenyl)oxazol-2-amine (61). A mixture of 2-bromo-1-
(4-bromophenyl)ethanone (200 mg, 0.72 mmol) and urea (435 mg, 7.2
mmol) in anhydrous acetonitrile (5 mL) was heated at 80 °C for 18 h.
The solvent was removed, and the residue was puriﬁed by ﬂash
chromatography (0−10% v/v MeOH in DCM) to aﬀord 61 (134 mg,
0.56 mmol, 78% yield) as a yellow solid. 1H NMR (400MHz, MeOD) δ
7.68 (s, 1H), 7.59−7.42 (m, 4H) ppm. 13C NMR (125 MHz, MeOD) δ
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163.9, 139.8, 132.7, 132.1, 128.8, 127.9, 122.1 ppm. LCMS (ESI+) m/z
238.8 [M + H]+, retention time 1.95 min (100%). HRMS (ESI+): m/z
calculated for C9H8BrN2O [M + H]
+: 238.9820. Found: 238.9816.
2. Enzyme Assay. The activity of Mth IMPDH ΔCBS was
determined using a plate reader bymonitoring the production of NADH
in absorbance at 340 nm and corrected for noncatalyzed chemical
reactions in the absence of Mth IMPDH ΔCBS. All the measurements
were done in the assay buﬀer (50mMTris HCl pH 8, 1mMDTT, 1mM
EDTA, and 100 mMKCl) at 37 °Cwith 20 nMMth IMPDHΔCBS, 2.8
mMNAD+, and 1mM IMP in a total of 150 μL volume in a 96 well plate-
based format, and data were collected for 32 min. The reaction was
initiated by the addition of the substrate, IMP, at a concentration of 1
mM. All reactions were performed in triplicate. Prior to reaction
initiation, the compounds were preincubated in a buﬀer with enzyme for
5 min. The inhibitors were dissolved in DMSO-d6 and diluted to a ﬁnal
concentration of 1% v/v in experimental reactions.
IC50 values were calculated by plotting the percentage of inhibition
against the logarithm of inhibitor concentration, and dose−response
curves were ﬁtted using Prism software (GraphPad).
The Ki value for NAD
+ was determined at a constant saturating IMP
concentration (1 mM) and ﬁve diﬀerent concentrations of NAD+ (0.35,
0.70, 1.0, 1.4, and 2.8 mM) in the presence of increasing concentrations
of inhibitor. The value of Ki for IMP was determined at ﬁxed saturating
concentration of NAD+ (2.8 mM) and diﬀerent concentrations of IMP
(0.12, 0.18, 0.25, 0.5, and 1 mM) and inhibitor.
The initial velocities at various inhibitor concentrations were
determined based on the slope in the linear part of each reaction
containing the inhibitor and the uninhibited reaction. To determine the
inhibition constant (Ki values), the initial rate data versus substrate
concentration at diﬀerent inhibitor concentrations were ﬁt using Prism
software (GraphPad) to equations for uncompetitive or mixed
inhibition. For each inhibitor concentration, the reciprocal of enzyme
reaction velocity versus the reciprocal of the substrate concentration was
plotted in a Lineweaver−Burk plot to determine the pattern of
inhibition.
3. Protein Puriﬁcation, Crystallization, and Data Collection of
Mth IMPDH ΔCBS. Mth IMPDH was expressed, puriﬁed, and
crystallized as previously described.24,25 Brieﬂy, hexahistidine tagged
Mth IMPDH ΔCBS in pHat2 was expressed overnight in BL21 DE3
(NEB) cells at 18 °C by addition of 500 μMIPTG. Cells were lysed in 50
mM Hepes, pH 8.0, 500 mM NaCl, 5% glycerol, 10 mM β-
mercaptoethanol, and 20 mM imidazole, and the recombinant protein
puriﬁed using a Hi-Trap IMAC FF column (GE Healthcare) charged
with nickel and an elution gradient of up to 300 mM imidazole. The
hexahistidine tag was cleaved by TEV protease, and the puriﬁed Mth
IMPDH ΔCBS was obtained by negative nickel gravity-ﬂow
puriﬁcation42 and size exclusion chromatography on a Superdex 200
gel ﬁltration column equilibrated in 20 mM Hepes pH 8.0, 500 mM
NaCl, 5% glycerol, and 1 mM TCEP step. The recombinant Mth
IMPDH ΔCBS was then concentrated to 12.5 mg/mL for
crystallization.
Mth IMPDHΔCBS protein crystallized in 1 μL + 1 μL hanging drops
with 100 mM sodium acetate, pH 5.5, 200 mM calcium chloride, and 8−
14% isopropanol. Crystals were soaked overnight in drops of well
solution + 5mM IMP and either 5mMFragment 2 or Compound 1 or 1
mM Compound 31. Crystals were cryoprotected by passing through
drops containing well solution + 25% glycerol and ﬂash-frozen in liquid
nitrogen. Data were collected from the crystals at Diamond Light Source
beamline.
4. Structure Solution, Ligand Fitting, and Reﬁnement. Data
were processed using XDS43 and Pointless (CCP4). To solve the
structure, molecular replacement was performed with Phenix Phaser44
using a previously solved IMP-boundMth IMPDHΔCBS structure as a
probe (PDB IDs: 5J5R; 5K4X; 5K4Z). Reﬁnement was performed using
Phenix.reﬁne and manually in Coot.45 IMP and the inhibitors were
sequentially ﬁtted into the density using the LigandFit function of
Phenix, and the structures were manually reﬁned further using Coot.
Information regarding the crystallographic statistics can be found in
Table S2. Protein−ligand interactions were analyzed using Arpeggio46
and CSM-Lig.47,48 Compound properties were evaluated using
pkCSM.49 All ﬁgures made using Pymol (Schrodinger).
5. Drug Susceptibility Testing against Mtb. An Alamar Blue
ﬂuorescence-based broth microdilution assay was used to assess the
minimum inhibitory concentration (MIC) of compounds against Mtb
H37Rv, as described previously.25,50 Brieﬂy, Mtb H37Rv was grown in
standard Middlebrook 7H9 broth (BD) supplemented with OADC
(BD), 0.2% glycerol, and 0.05% Tween-80 to midexponential phase.
Compounds dissolved in DMSO (1%) were tested in clear-bottomed,
round-well 96-well microtiter plates at eight diﬀerent concentrations
using the standard anti-TB drugs, rifampin and isoniazid, as positive
controls. An inoculum of ∼105 bacteria was added to each well, and the
plates were incubated at 37 °C for 7 d. On day 7, 10 μL of Alamar Blue
(Invitrogen) was added to each well, and plates were further incubated
at 37 °C for 24 h. The ﬂuorescence (excitation 544 nm; emission 590
nm) was measured in a FLUOstar OPTIMA plate reader (BMG
LABTECH, Oﬀenberg, Germany). Data were normalized to the
minimum and maximum inhibition controls to generate a dose response
curve (% inhibition) from which the MIC90 was determined.
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